Three big things need to happen for a cure for type 1 diabetes to be successful, and we’ve already crossed one of them off the list. Learn the latest research from three companies at the forefront of discovery, and find out when we think a functional cure will be realized (hint: It may be sooner than you think).
read more →
2025 is shaping up to be a blockbuster year in diabetes care! From smart MDI systems to medications that pull triple duty, the future is looking smarter—and less invasive.
Here are several key advancements we expect to see in 2025.
After seeing the struggles her patients faced living with type 1 diabetes, Dr. Tina Gupta was compelled to do more to help. She left clinical practice and joined Vertex Pharmaceuticals, a company researching treatment therapies that replace non-functioning beta cells with stem-cell- derived cells to try to reduce or eliminate the need for people with T1D to take insulin.
read more →
Vertex Pharmaceuticals is relatively new to the type 1 diabetes space, and they are working hard to understand what it’s like for people to live with T1D so they can develop transformative therapies. They’re currently investigating and advancing cell therapies aimed at treating an underlying cause of type 1 – the absence of insulin-producing cells.
read more →
Our international panel of diabetes experts discussed highlights from the ADA’s Scientific Sessions, and lead a Q&A on some of the most important advances in diabetes.
read more →
